Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. [electronic resource]
Producer: 20040601Description: 114-9 p. digitalISSN:- 1527-9995
- 5-alpha Reductase Inhibitors
- Adenocarcinoma -- blood
- Androgen Antagonists -- administration & dosage
- Androstenediols -- blood
- Benzoquinones -- administration & dosage
- Biomarkers, Tumor -- blood
- Chemical and Drug Induced Liver Injury -- etiology
- Dihydrotestosterone -- blood
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Enzyme Inhibitors -- administration & dosage
- Estradiol -- blood
- Humans
- Isoenzymes -- antagonists & inhibitors
- Life Tables
- Male
- Neoplasm Proteins -- antagonists & inhibitors
- Orchiectomy
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- blood
- Safety
- Substrate Specificity
- Testosterone -- blood
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.